DDInter1679 DDInter915
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Sitagliptin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Sitagliptin {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Sitagliptin {u} (Compound) downregulates {v} (Gene) IL4R
IL4R {u} (Gene) is associated with {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) palliates {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Epinephrine {u} (Compound) palliates {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Sitagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Sitagliptin (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Sitagliptin (Compound) downregulates IL4R (Gene) and IL4R (Gene) is associated with asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) palliates asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) palliates asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)